Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
165.2 SAR | -1.90% | -1.67% | -3.84% |
May. 13 | Dallah Healthcare Posts Higher Q1 Net Profit, Revenue | MT |
Mar. 20 | Dallah Healthcare Company Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The group's high margin levels account for strong profits.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company is in debt and has limited leeway for investment
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 36.97 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-3.84% | 4.39B | - | ||
-17.57% | 16.76B | B+ | ||
+3.60% | 12.65B | B | ||
+4.64% | 11.86B | B+ | ||
+4.28% | 10.28B | B+ | ||
+29.06% | 8.67B | B | ||
-6.94% | 7.6B | A- | ||
+6.55% | 6.8B | B- | ||
+8.77% | 6.52B | D | ||
+46.39% | 4.53B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 4004 Stock
- Ratings Dallah Healthcare Company